Pathophysiology of myeloma bone disease

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 4, 2007, Pages 613-624

  Esteve, Flavia R ^a   Roodman, G David ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

bone destruction; metastasis; myeloma; osteoclasts

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; BORTEZOMIB; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; DENOSUMAB; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PROTEIN P62; SCIO 469; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; WNT PROTEIN; ZOLEDRONIC ACID;

BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE REMODELING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DEATH; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; GENE EXPRESSION; GENETIC CORRELATION; HUMAN; HYPERCALCEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MONOTHERAPY; MULTIPLE MYELOMA; NEPHROLITHIASIS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; UNITED STATES;

BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; HUMANS; MULTIPLE MYELOMA; OSTEOCLASTS; RANK LIGAND;

EID: 36749056256     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.08.003     Document Type: Review

References (75)

1. Roodman G.D. Cell Biology of the osteoclast. Experimental Hematology 27 (1999) 1229-1241
2. Roodman GD. Treatment strategies for bone disease. Bone Marrow Transplantation 2007 Aug 6. [Epub ahead of print].
3. Gunn W.G., Conley A., Deininger L., et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24 (2006) 986-991
4. Giuliani N., Colla S., and Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator NF-Kappa-B ligand (RANKL). Experimental Hematology 32 (2004) 685-691
5. Choi S.J., Cruz J.C., Craig F., et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96 (2000) 671-675
6. Lee J.W., Chung H.Y., Ehrlich L.A., et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103 (2004) 2308-2315
7. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 3540-3545
8. Nakagava N., Kinosaki M., Yamaguchi K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochemical and Biophysical Research Communications 253 (1998) 395-400
9. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
10. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 3597-3602
11. Hofbauer L.C., and Heufelder A.E. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. European Journal of Endocrinology 139 (1998) 152-154
12. Tsukii K., Shima N., Mochizuki S., et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochemical and Biophysical Research Communications 246 (1998) 337-341
13. Dougall W.C., Glaccum M., Charrier K., et al. RANK is essential for osteoclast and lymph node development. Genes & Development 13 (1999) 2412-2424
14. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
15. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
16. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes & Development 12 (1998) 1260-1268
17. Li J., Sarosi I., Yan X.Q., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 1556-1571
18. Pearse R.N., Sordillo E.M., Yaccoby S., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America 98 (2001) 11581-11586
19. Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor kappaB ligand- osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
20. Yaccoby S., Pearse R.N., Johnson C.L., et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British Journal of Haematology 116 (2002) 278-290
21. Han J.H., Choi S.J., Kurihara N., et al. Macrophage inflammatory protein-1 alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97 (2001) 3349-3353
22. Magrangeas F., Nasser V., Avet-Loiseau H., et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101 (2003) 4998-5005
23. Hashimoto T., Abe M., Oshima T., et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1 alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. British Journal of Haematology 125 (2004) 38-41
24. Alsina M., Boyce B., Devlin R.D., et al. Development of an in vivo model of human multiple myeloma bone disease. Blood 87 (1996) 1495-1501
25. Choi S.J., Oba Y., Gazitt Y., et al. Antisense inhibition of macrophage inflammatory protein 1 alpha block bone destruction in a model of myeloma bone disease. The Journal of Clinical Investigation 108 (2001) 1833-1841
26. Masih-Khan E., Trudel S., Heise C., et al. MIP-1a (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 108 (2006) 3465-3471
27. Ehrlich L.A., Chung H.Y., Ghobrial I., et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106 (2005) 1407-1414
28. Solary E., Guiguet M., Zeller V., et al. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. American Journal of Hematology 39 (1992) 163-171
29. Sai H.I., Apperley J.F., Graves M., et al. Interleukin -6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of unknown significance. British Journal of Haematology 101 (1998) 287-295
30. Karadag A., Oyajobi B.O., Apperley J.F., et al. Human myeloma cells promote the production of interleukin-6 by primary human osteoblasts. British Journal of Haematology 108 (2000) 383-390
31. Abe M., Hiura K., Wilde J., et al. Osteoclasts enhance myeloma cell growth and survival via cell to cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104 (2004) 2484-2491
32. Nguyen A.N., Sttebbins E.G., Henson M., et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Experimental Cell Research 312 (2006) 1909-1923
33. Vanderkerken K., Medicherla S., Coulton L., et al. Inhibition of p38a MAPK reduces tumor burden, prevents the development of myeloma bone disease, and increases survival in the 5T2 and 5T3 murine models of myeloma. Blood 108 (2006) 981a [abstract 3436]
34. Kurihara N., Hiruma Y., Hong C.S., et al. targeting p62 in marrow stromal cells is effective at inhibiting myeloma cell growth. Blood 108 (2006) 155a [abstract 513]
35. Bataille R., Chappard D., Marcelli C., et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. Journal of Clinical Oncology 7 (1989) 1909-1914
36. Bataille R., Chappard D., Marcelli C., et al. Osteoblast stimulation in multiple myeloma lacking bone lytic lesions. British Journal of Haematology 76 (1990) 484-487
37. Hjorth-Hansen H., Seifert M.F., Borset M., et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. Journal of Bone and Mineral Research 14 (1999) 256-263
38. Kobayashi T., and Kronenberg H. Mini review: transcriptional regulation in development of bone. Endocrinology 146 (2005) 1012-1017
39. Ducy P., Zhang R., Geoffroy V., et al. Osf2/Cbfal: a transcriptional activator of osteoblast differentiation. Cell 89 (1997) 747-754
40. Franceschi R.T., and Xiao G. Regulation of the osteoblast specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. Journal of Cellular Biochemistry 88 (2003) 446-454
41. Karsenty G., Ducy P., Starbuck M., et al. Cbfal as a regulator of osteoblast differentiation and function. Bone 25 (1999) 107-108
42. Komori T. Runx2, a multifunctional transcription factor in skeletal development. Journal of Cellular Biochemistry 87 (2002) 1-8
43. Giuliani N., Colla S., Morandi F., et al. Myeloma cells block RUNX2/CBFAL1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106 (2005) 2472-2483
44. Thirunavukkarasu K., Halladay D.L., Miles R.R., et al. The osteoblast-specific transcription factor Cbfal contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. The Journal of Biological Chemistry 275 (2000) 25163-25172
45. Barille S., Collette M., Bataille R., et al. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell to cell contact but downregulate osteocalcin. Blood 86 (1995) 3151-3159
46. Ely S.A., and Knowles D.M. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. The American Journal of Pathology 160 (2002) 1293-1299
47. Roodman G.D. New Potential targets for treating myeloma bone disease. Clinical Cancer Research 12 (2006) 6270s-6273s
48. Lee S.K., Kalinowski J.F., Jacquin C., et al. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. Journal of Bone and Mineral Research 21 (2006) 695-702
49. Toraldo G., Roggia C., Qian W.P., et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappaB ligand and tumor necrosis factor alpha from T cells. Proceedings of the National Academy of Sciences of the United States of America 100 (2003) 125-130
50. Qiang Y.-W., Endo Y., Rubin J.S., et al. Wnt signaling in B cell neoplasia. Oncogene 22 (2003) 1536-1545
51. Gong Y., Slee R.B., Fukai N., et al. LDL receptor-related protein (LRP5) affects bone accrual and eye development. Cell 107 (2001) 513-523
52. Westerndorf J.J., Kahler R.A., and Schroeder T.M. Wnt signaling in osteoblasts and bone diseases. Gene 341 (2004) 19-39
53. Rawadi G., Vayssiere B., Dunn F., et al. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. Journal of Bone and Mineral Research 18 (2003) 1842-1853
54. Mukhopadhyay M., Shtrom S., Rodriguez-Esteban C., et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Developmental Cell 1 (2001) 423-434
55. Grotewold L., and Ruther U. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulated programmed cell death. The EMBO Journal 21 (2002) 966-975
56. Morvan F., Boulukos K., Clement-Lacroix P., et al. Deletion of a single allele of the Dkk-1 gene leads to an increase in bone formation and bone mass. Journal of Bone and Mineral Research 21 (2006) 934-954
57. Li J., Sarosi I., Cattley R.C., et al. Dkk-1 mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39 (2006) 754-766
58. Tian E., Zhan F., Walker R., et al. The role of Wnt signaling antagonist DKK-1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine 349 (2003) 2483-2494
59. Politou M.C., Health D.J., Rahemtulla A., et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. International Journal of Cancer 119 (2006) 1728-1731
60. Glass D.A., Bialek P., Ahn J.D., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell 8 (2005) 751-764
61. Spencer G.J., Utting J.C., Etheridge S.L., et al. Wnt signaling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. Journal of Cell Science 119 (2006) 1283-1296
62. Oshima T., Abe M., Asano J., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor sFRP-2. Blood 106 (2005) 3160-3165
63. Oyajobi B.O., and Mundy G.R. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein 1-alpha and the proteasome. Cancer 97 (2003) 813-817
64. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. The New England Journal of Medicine 334 (1996) 448-493
65. Lacy M.Q., Dispenzieri A., Gertz M.A., et al. mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clinic proceedings 81 (2006) 1047-1053
66. Body J.J., Facon T., Coleman R.E., et al. A study of the biological receptor activator of nuclear factor kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clinical Cancer Research 12 (2006) 1221-1228
67. Mbalaviele G., Anderson G., Jones A., et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. The Journal of Pharmacology and Experimental Therapeutics 317 (2006) 1044-1053
68. Rossa C., Ehmann K., Liu M., et al. MKK3/6-p38 MAPK signaling is required for IL-1 beta and TNF alpha induced RANKL expression in bone marrow stromal cells. Journal of Interferon & Cytokine Research 26 (2006) 719-729
69. Zangari M., Yaccoby S., Cavallo F., et al. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clinical Lymphoma & Myeloma 7 (2006) 109-114
70. Heider U., Kaiser M., Muller C., et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. European Journal of Haematology 77 (2006) 233-238
71. Garrett I.R., Chen D., Gutierrez G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. The Journal of Clinical Investigation 111 (2003) 1117-1182
72. Terpos E., Heath D., Rahemtulla A., et al. Bortezomib reduces serum dicckopf-1 and RANKL concentrations and normalizes indices of bone remodeling in patients with relapsed multiple myeloma. Blood 108 (2006) 153a [abstract 506]
73. Oba Y., Lee J.W., Ehrlich L.A., et al. MIP-1 alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Experimental Hematology 3 (2005) 272-278
74. Lentzsch S., Gries M., Janz M., et al. Macrophage inflammatory protein 1-alpha triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma cells. Blood 101 (2003) 3568-3573
75. Pennisi A., Ling W., Perkins P., et al. PTH and Bortezomib suppress growth of primary human myeloma cells through increased bone formation in vivo. Blood 108 (2006) 154a [abstract 509]